ABSTRACT
The role of chemotherapy in the treatment of endometrial cancer is evolving rapidly. For many years, the mainstay of treatment for uterine cancer was surgery with or without radiotherapy depending on the stage of disease. Chemotherapy was mainly used in the palliative setting, with little benefit. Newer combination chemotherapy regimens developed over the past few years have shown high response rates which will hopefully translate into longer survival with acceptable toxicity for patients with advanced disease. Novel agents are also being extensively tested in clinical trials. Chemotherapy is now moving into first-line treatment for patients with stage III and IV disease, and often for those with high-risk features such as serous papillary and clear cell histology. The major questions that need answers include:
1. What is the role of radiation therapy when chemotherapy is given in the adjuvant setting?
